Celsion Corporation (NASDAQ:CLSN) is set to announce third quarter earning results on Monday 16th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, CLSN to report 3Q20 loss of $ 0.13 per share.
For the full year, analysts anticipate top line of $ 0.38 million, while looking forward to loss of $ 0.63 per share bottom line.
Previous Quarter Performance
Celsion Corporation revealed loss for the second quarter of $ 0.18 per share, from the revenue of $ 0.12 million. The quarterly revenues contracted 7.69 percent compared with the same quarter last year. Street analysts expected Celsion Corporation to report loss of $ 0.14 per share on revenue of $ 0.08 million for the second quarter. The bottom line results missed street analysts by $ 0.04 or 28.57 percent, at the same time, top line results outshined analysts by $ 0.04 million or 50.00 percent.
Stock Performance
On Friday, shares of Celsion Corporation has traded high as $ 0.56 and has cracked $ 0.51 on the downward trend, reaching $ 0.54 with volume of 683.80 thousand shares.
According to the previous trading day, closing price of $ 0.54, representing a 18.60 % increase from the 52 week low of $ 0.43 and a 92.15 % decrease over the 52 week high of $ 6.50.
The company has a market capital of $ 19.45 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Celsion Corporation will be hosting a conference call at 11:00 AM eastern time on 16th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 1-800-367-2403 (United States) or 1-334-777-6978 (International), and the passcode is 8337630 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.celsion.com
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers.
